Piramal Pharma Limited (PPLPHARMA:NSE) Annual Income Statement ()
PPLPHARMA:NSE Quarterly Financials ()
Frequently Asked Questions About Piramal Pharma Limited (PPLPHARMA:NSE) Stock
Piramal Pharma Limited's (PPLPHARMA:NSE) last reported annual revenue was INR 70.82 Billion.
Piramal Pharma Limited's (PPLPHARMA:NSE) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
Piramal Pharma Limited's(PPLPHARMA:NSE) is not profitable as of its last reported annual financials.
The net profit margin for Piramal Pharma Limited's(PPLPHARMA:NSE) from its laster reported year is -2.63%
The return on equity (ROE) for Piramal Pharma Limited's(PPLPHARMA:NSE) from its last reported annual financials is : -1.85%
The return on assets (ROA) for Piramal Pharma Limited's(PPLPHARMA:NSE) from its last reported annual financials is : 0.85%
The return on invested capital (ROIC) for Piramal Pharma Limited's(PPLPHARMA:NSE) from its last reported annual financials is : -0.88%
The Debt to Equity ratio for Piramal Pharma Limited's(PPLPHARMA:NSE) from its last reported annual financials is : 0.00%
The dividend yield for Piramal Pharma Limited's(PPLPHARMA:NSE) from its laster reported year is 0.00%
Piramal Pharma Limited's(PPLPHARMA:NSE) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PPLPHARMA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
